These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 35582722)

  • 1. Emerging targets in cancer drug resistance.
    Kumar S; Kushwaha PP; Gupta S
    Cancer Drug Resist; 2019; 2(2):161-177. PubMed ID: 35582722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.
    Shibata T; Kokubu A; Gotoh M; Ojima H; Ohta T; Yamamoto M; Hirohashi S
    Gastroenterology; 2008 Oct; 135(4):1358-1368, 1368.e1-4. PubMed ID: 18692501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of FOXO protein's abnormal activation through PI3K/AKT pathway in platinum resistance of ovarian cancer.
    Shi YY; Meng XT; Xu YN; Tian XJ
    J Obstet Gynaecol Res; 2021 Jun; 47(6):1946-1957. PubMed ID: 33827148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease.
    Tebay LE; Robertson H; Durant ST; Vitale SR; Penning TM; Dinkova-Kostova AT; Hayes JD
    Free Radic Biol Med; 2015 Nov; 88(Pt B):108-146. PubMed ID: 26122708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy.
    Wilson MS; Brosens JJ; Schwenen HD; Lam EW
    Curr Drug Targets; 2011 Aug; 12(9):1256-66. PubMed ID: 21443467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance.
    Zhao F; Lam EW
    Front Med; 2012 Dec; 6(4):376-80. PubMed ID: 23124885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
    McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
    J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXO Signaling Pathways as Therapeutic Targets in Cancer.
    Farhan M; Wang H; Gaur U; Little PJ; Xu J; Zheng W
    Int J Biol Sci; 2017; 13(7):815-827. PubMed ID: 28808415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of Evidence-Based Chemotherapy for Oral Cancer: Focus on Drug Resistance Related to the Epithelial-Mesenchymal Transition.
    Sha J; Bai Y; Ngo HX; Okui T; Kanno T
    Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34208465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Nrf2 may reverse the drug resistance in ovarian cancer.
    Li D; Hong X; Zhao F; Ci X; Zhang S
    Cancer Cell Int; 2021 Feb; 21(1):116. PubMed ID: 33596893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth.
    Zhang P; Singh A; Yegnasubramanian S; Esopi D; Kombairaju P; Bodas M; Wu H; Bova SG; Biswal S
    Mol Cancer Ther; 2010 Feb; 9(2):336-46. PubMed ID: 20124447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of the Nrf2-Keap1 signaling pathway in cancer.
    Jaramillo MC; Zhang DD
    Genes Dev; 2013 Oct; 27(20):2179-91. PubMed ID: 24142871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2.
    Wang XJ; Sun Z; Villeneuve NF; Zhang S; Zhao F; Li Y; Chen W; Yi X; Zheng W; Wondrak GT; Wong PK; Zhang DD
    Carcinogenesis; 2008 Jun; 29(6):1235-43. PubMed ID: 18413364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of Akt activity by chemotherapy confers acquired resistance.
    Huang WC; Hung MC
    J Formos Med Assoc; 2009 Mar; 108(3):180-94. PubMed ID: 19293033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wnt/beta-catenin and PI3K/Akt/mTOR Signaling Pathways in Glioblastoma: Two Main Targets for Drug Design: A Review.
    Shahcheraghi SH; Tchokonte-Nana V; Lotfi M; Lotfi M; Ghorbani A; Sadeghnia HR
    Curr Pharm Des; 2020; 26(15):1729-1741. PubMed ID: 32003685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dictyostelium discoideum to human cells: pharmacogenetic studies demonstrate a role for sphingolipids in chemoresistance.
    Alexander S; Min J; Alexander H
    Biochim Biophys Acta; 2006 Mar; 1760(3):301-9. PubMed ID: 16403600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Keap1-Nrf2 cell defense pathway--a promising therapeutic target?
    Copple IM
    Adv Pharmacol; 2012; 63():43-79. PubMed ID: 22776639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resist or die: FOXO transcription factors determine the cellular response to chemotherapy.
    Gomes AR; Brosens JJ; Lam EW
    Cell Cycle; 2008 Oct; 7(20):3133-6. PubMed ID: 18927504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of PI3K/AKT/FOXO signaling in psoriasis.
    Zhang M; Zhang X
    Arch Dermatol Res; 2019 Mar; 311(2):83-91. PubMed ID: 30483877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.